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Abstract
Background: We have surveyed, compiled and annotated nucleotide variations in 338 human 7-
transmembrane receptors (G-protein coupled receptors). In a sample of 32 chromosomes from a
Nordic population, we attempted to determine the allele frequencies of 80 non-synonymous SNPs,
and found 20 novel polymorphic markers. GPCR receptors of physiological and clinical importance
were prioritized for statistical analysis. Natural variation and rare mutation information were
merged and presented online in the Human GPCR-DB database http://cyrix.cgb.ki.se.
Results: The average number of SNPs per 1000 bases of exonic sequence was found to be twice
the average number of SNPs per Kilobase of intronic regions (2.2 versus 1.0). Of the 338 genes,
111 were single exon genes, that is, were intronless. The average number of exonic-SNPs per
single-exon gene was 3.5 (n = 395) while that for multi-exon genes was 0.8 (n = 1176). The average
number of variations within the different protein domain (N-terminus, internal- and external-loops,
trans-membrane region, C-terminus) indicates a lower rate of variation in the trans-membrane
region of Monoamine GPCRs, as compared to Chemokine- and Peptide-receptor sub-classes of
GPCRs.
Conclusions: Single-exon GPCRs on average have approximately three times the number of SNPs
as compared to GPCRs with introns. Among various functional classes of GPCRs, Monoamine
GPRCs have lower number of natural variations within the trans-membrane domain indicating
evolutionary selection against non-synonymous changes within the membrane-localizing domain of
this sub-class of GPCRs.
Background
The 7TM (7 trans-membrane domain proteins) genes,
also known as the hetero-trimeric GTP-binding protein (G
protein)-coupled receptors (GPCRs), are members of a
large family of genes with an estimated 700 members in
the human genome [1]. These receptors are plasma mem-
brane-bound and have evolved to respond to a large
number of extracellular and chemical signals. Upon inter-
action with their ligands, GPCRs act through the G pro-
teins in signaling pathways that influence physiological
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functions. All GPCRs, in spite of great diversity in
sequence composition, share a common protein struc-
ture. An N-terminal extracellular domain of variable
length is followed by seven hydrophobic transmembrane-
helices, connected by three intracellular (IL) and three
extracellular (EL) loops, which then terminates in a C-ter-
minal intracellular domain [2]. The functional and struc-
tural role of the different domains has been elucidated by
systematic point mutations and crystal structure analysis
for many of the human GPCR proteins. Several studies
have collectively analyzed the occurrence, and importance
of coding GPCR SNPs [3-5] and also the relevance and
importance of mutations within these genes for the phar-
maceutical industry [6]. The functional significance of
thousands of point mutations has been described by a
large number of investigations as evident at NCBI's
PubMed Central. Mutation databases dedicated to GPCR
mutations are currently available online like GPCR DB [7]
and tinyGRAP [8]. Although an extensive collection of
mutations is available at these sources, the distribution of
these mutations and variations within the gene or pep-
tide, along with common SNPs is not easily accessible or
evident. The SNP databases in public domain (for exam-
ple: NCBI's dbSNP) have highlighted all non-synony-
mous SNPs (nsSNPs). Also HGVBase http://
hgvbase.cgb.ki.se/ has further classified the location of the
amino acid within the encoded proteins to more accu-
rately predict the detrimental effects of a change in pep-
tide sequence. From a pharmacogenetics viewpoint, the
information about natural variations within GPCR tran-
scripts and peptides, with allele frequency and validation
data and disease association, is an important, yet currently
unavailable, public resource. A database with functional
promoter SNP, allele frequency, peptide variation infor-
mation, population and haplotype information presented
in a graphically accessible format would facilitate pharma-
cogenomics research related to GPCR proteins. HUMAN
GPCR-DB aims to provide such a public resource. Also the
rate of false positive SNPs determined experimentally in
GPCR genes is reported to be relatively high [5]. For typi-
cal case-control association studies, prevailing designs
favor highly polymorphic loci as against loci where the
frequency of the minor allele is below 10%. Therefore
more nsSNPs need to be validated and frequencies deter-
mined across ethnically diverse populations. We have
designed genotyping assays and attempted to validate a
number of GPCR nsSNPs for which no validation infor-
mation was available on public databases, and deposited
the validation information at HUMAN GPCR-DB. We
have also collected published literature SNPs and added
to our online database.
Several recent studies have focused on the subset of nsS-
NPs that most likely influence phenotype [9-13]. Com-
paratively, fewer attempts have been made on predicting
and validating functional promoter SNPs [14]. As a part of
a parallel work, we have developed a streamlined bioin-
formatics and wet-lab analysis methods to identify puta-
tive functional promoter SNPs with up to 70% probability
of influencing gene expression. By applying this analysis
package to all of the 338 genes in our database, we have
highlighted, putative functional promoter SNPs. HUMAN
GPCR-DB also attempts to merge SNP and other varia-
tions from published articles from PubMed and online
SNP databases to facilitate direct identification of the
functional significance of a natural variation.
Results
A total of 427 non-redundant Human GPCR peptides
were obtained from Swissprot of which 338 had Swissprot
ID and the remaining had only TrEMBL identifications.
Also, 89 of the 427 GPCR were classified as olfactory
receptors. While all of the 427 entries were included in the
HUMAN GPCR-DB database, only non-olfactory (i.e.
338) were considered for further analysis of gene struc-
ture, alternative transcripts, SNPs, and protein variations.
Although the TrEMBL entries have also been included, the
data displayed for these entries would be more accurately
presented in future updates of the database. The statistical
calculations for the genomic SNPs are based on the 338
non-olfactory entries, while the data for nsSNPs encoding
peptide variations is based on 222 entries for which there
are documented evidence for a 7-TM domain structure.
Transcript information for each gene was used for calcu-
lating average exonic and intronic SNPs. For genes with
multiple transcript variants, the longest transcript was
selected. Average number of SNPs per exon (n = 1511) of
the 338 genes was one, while the average number of SNPs
per intron (n = 1174) was nine. However, the average
number of SNPs per 1000 bases of exonic sequence was
twice the average number of SNPs per kilobase of intronic
regions (2.2 versus 1.0). Of the 338 genes, 111 were single
exon genes, that is, were intronless. The average number
of exonic-SNPs per single-exon gene was 3.5 (n = 395)
while that for multi-exon genes was 0.8 (n = 1176). This
observation is in agreement with earlier observation based
on a smaller number of GPCRs, where, compared to
intronless GPCRs, exons in genes with introns on average
had fewer SNPs [15].
Of the 1511 SNPs from the exons of 338 GPCR tran-
scripts, 816 SNPs were coding SNPs, among which 392
were nsSNP; 211 of which had no validation information
in either of the source databases, i.e. NCBI/dbSNP and
HGVBase. The number of validated and non-validated
SNPs is shown in Table 1. By excluding genes with 'prob-
able', 'putative', 'precursor' and other ambiguous terms as
a part of their description (as designated by Ensembl), we
reduced the number of SNPs from 211 to 123 non-vali-BMC Genomics 2004, 5:91 http://www.biomedcentral.com/1471-2164/5/91
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dated, nsSNPs which were considered as our list of prime
candidates for the wet-lab validation process (Table 2). As
a part of our first stage validation process, we designed
assays for 80 of the 123 SNPs in GPCR genes of interest
based on our better understanding of their role in human
disease and physiology. Finally, of the 80 assayed SNPs,
20 were found to be polymorphic in our Nordic popula-
tion sample consisting of DNA from 16 un-related healthy
individuals. Of the 20 polymorphic markers 12 had a
minor allele frequency higher than 10%.
Table 2 shows the number of GPCRs categorized by differ-
ent criteria, and SNPs categorized in the two groups of val-
idate and non-validated nsSNPs. Of the 338 genes, 222
had a documented GPCR structure as described by SWISS-
PROT/TrEMBL database. The total number of nsSNPs in
this subset of 222 proteins was 283, of which 112 had val-
idation information (leaving 171 with no validation
information). To these we added 120 SNPs from Pubmed
reports [14]. The identity of the 120 variations from pub-
lished reports was verified to be SNPs and not rare muta-
tions. Therefore a significant proportion of 'disease
causing', rare variations were eliminated since they were
reported from rare family based disease cases. These 120
SNPs are represented in the HUMAN GPCR-DB as 'rs-
missing' since dbSNP records for many of these were not
found. As future updates from dbSNP assign rs-IDs to the
new SNPs, our database would update the records
likewise.
According to the International Union of Pharmacology
http://www.iuphar.org, 101 GPCRs from 338 were cate-
gorized either as 'peptide receptors' (n = 47) or 'chemok-
ine receptors' (n = 54) or 'monoamine receptors' (n = 36).
The distribution of nsSNPs across the 5 structural and
functional domains (N-terminus, external loops, trans-
membrane, internal loops and C-terminus) of these 101
GPCRs was calculated (Table 3). These 101 GPCRs have in
total 182 nsSNPs, of which 53 SNPs have validation infor-
mation in the major public databases. To these 53 SNPs
we added 86 SNPs from published PubMed sources [14],
bringing the total number of validated SNPs, used for this
analysis, to 136 SNP. The 20 SNPs validated in this study
were not included for this analysis since we wanted to
analyze publicly available data only, at this time. The dis-
tribution of nsSNP numbers was compared between indi-
vidual groups (monoamines-receptors only, or
chemokine-receptors only or peptide-receptors only) and
in various combinations with other two groups
(monoamines plus chemokines or peptides plus
monoamine, etc). None of the groups of receptors devi-
ated from the mean of the three groups together, in any
significant way. The N-terminus and external-loop SNPs
were then combined in one group, and C-terminus and
internal-loop SNPs in another group, and compared with
nsSNPs in TM region. The nsSNP distribution in the three
domains approached significance (Pearson's p-value
0.06) in the Monoamine sub-group of GPCRs. We then
calculated the average number of nsSNP per 1000 bases of
Table 1: Distribution of validated and non-validated SNPs.
Synonymous SNPs Non-synonymous SNPs Total SNPs
Validated SNPs 212 181 393
Non-validated SNPs 212 211 423
Total 424 392 816
The number of synonymous and non-synonymous SNPs and those with validation information, as deposited at NCBI/dbSNP, during 2003–4.
Table 2: Number of GPCRs in validated and non-validated categories.
Nr. of GPCR genes Total nsSNPS Validated nsSNPs Non-validated nsSNPs This study
338 (genes classified as 
GPCRs)
392 181 211 (123 were considered 
for validation).
80 of 123 assayed. 20 were 
polymorphic
222 (bearing evidence for 
7-TM domains)
283 112 (Added 120 from [16]) 171
101 (classified in 3 sub-
groups – Monoamine, 
Peptide and Chemokine).
182 53 (Added 83 from [16]) = 
136 (used in Table 3).
The initial 338 GPCRs were selected as per annotation by Ensembl. Support for structural evidence of 222 GPCRs was obtained from SWISSPROT. 
Classification of GPCRs was obtained from GPCRDB http://www.gpcr.org/7tm, Ensembl http://www.ensembl.org, International Union of 
Pharmacology http://www.iuphar.org.BMC Genomics 2004, 5:91 http://www.biomedcentral.com/1471-2164/5/91
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each of the 5 domains. The average number of nsSNPs in
the TM region of Monoamine receptors (two SNPs per
kilobase) was half of the average for each of the other
groups (four or five nsSNPs per kilobase). This difference
was not observed for any of the other four (N-term, e- and
i-loops and C-term) structural domains of the peptides
(Table 3).
We compiled together the functional properties of peptide
variations from published records along with the knowl-
edge of the location and the two alleles of a nsSNP in our
database. Searching PubMed records, we found 38 nsS-
NPs located in the precise position, and substituting the
same amino acid, as those studied for functional analysis
shown in Table 4 [See additional file 1].
Database interface and layout
The HUMAN GPCR-DB is currently online http://
cyrix.cgb.ki.se. This database allows for 3 alternative que-
ries, either Ensembl gene ID, or Swissprot/TrEMBL ID or
part of the gene name or description. Resulting hits are
displayed along with total number of coding SNPs and
protein variations. These links in turn display a graphic
representation of the SNP locations within exons (or pep-
tide) and the query gene. The exons are drawn in propor-
tion to the largest exon, while the introns are of fixed
length. The SNP list provides allele information, flanking
sequences (for assay development and strand verification,
etc) and links for validation information and source data-
bases. The promoter information is drawn in a similar
manner, with mouse conserved regions indicated with
green bars underneath and SNPs within conserved regions
marked with a symbol 'M' in the SNP full-list. SNPs pre-
dicted to influence protein binding according to our pre-
diction model are marked 'T' in the SNP full-list. The link
for protein variations displays a window with SNP,
marked in red arrows, and mutation distribution across 3
regions of the peptide; N-terminus, C-terminus and trans-
membrane and loop regions. Association with diseases
and the corresponding PubMed ID are displayed as a
popup menu following the link under 'disease' column.
Discussion
We have constructed a database, which combines muta-
tion information with validated SNP information from
publicly available sources. We have then attempted to val-
idate and determine the frequencies of 80 of the 123 non-
synonymous SNPs for which no validation information
was available publicly. Proportion of true polymorphic
loci was 20%, in agreement with reported expectations
from several studies [5].
The statistical approach for the analysis of distribution of
natural variations in GPCRs, presented here is borrowed
from two recent studies [15,16]. While in the first of these
studies [15] 64 GPCR genes were sequenced in 82
individuals of divergent ethnic backgrounds and resulting
frequency distribution of nsSNPs were compared with
non-GPCR genes, the later study [16] analyzed differences
in distribution of published and publicly available nsSNP
in 62 GPCR genes, across the 5 peptide domains. For our
current report we analyzed 222 GPCR genes with over 200
nsSNPs (283 snSNPs available on public databases, and
120 nsSNP from PubMed records) [16]. Transcripts lack-
ing introns had on average higher density of SNPs (2-fold)
than those with introns, in agreement with an earlier pub-
Table 3: SNP distribution in peptide domains.
Peptide domain Genes N-term e-loop TM i-loop c-term p-value N-term 
+ e-loop
TM C-term 
+ i-loop
p-value
Monoamine + 
Peptide + 
Chemokines
101 20 (3.7) 17 (3.6) 43 (3.0) 29 (3.5) 27 (4.5) 37 (3.7) 43 (3.0) 56 (4.0)
Monoamine Only 36 7 (5.7) 6 (3.9) 11 (1.9) 16 (3.3) 18 (3.9) 0.26 13 (4.7) 11 (1.9) 34 (3.5) 0.06
Peptide Only 47 10 (2.9) 8 (3.9) 25 (4.2) 11 (4.3) 15 (5.7) 0.89 18 (3.3) 25 (4.2) 26 (5.0) 0.79
Chemokine Only 18 3 (4.0) 3 (2.8) 7 (2.5) 2 (2.5) 4 (4.5) 0.87 6 (3.3) 7 (2.5) 6 (3.5) 0.72
Chemokine + 
Monoamine
54 10 (5.1) 9 (3.4) 18 (2.1) 18 (3.2) 12 (4.1) 0.93 19 (4.1) 18 (2.1) 30 (3.5) 0.78
Peptide + 
Monoamine
83 17 (3.7) 14 (3.9) 36 (3.2) 27 (3.6) 23 (4.9) 0.94 31 (3.8) 36 (3.2) 50 (4.2) 0.96
Chemokine + 
Peptide
65 13 (3.1) 11 (3.5) 32 (3.7) 13 (3.8) 19 (5.4) 0.87 24 (3.3) 32 (3.7) 32 (4.6) 0.71
Total number of nsSNP in various domains of 3 subgroups of GPCR proteins.
Abbreviations: N-term : N terminus; C-term : C terminus; i-loop : internal loops; e-loop : external loops; TM: trans-membrane. The numbers in the 
brackets are the average number of SNPs per 1000 base pairs of a specific domain. The Fisher's Exact p-values were calculated using a 5 × 2 
contingency table at http://home.clara.net/sisa/fiveby2.htm. Contingency tables of 2 × 3 were constructed at http://www.physics.csbsju.edu/stats/
contingency.html. P-values of below or close to 0.05 are considered significant.BMC Genomics 2004, 5:91 http://www.biomedcentral.com/1471-2164/5/91
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lished report [15]. The distribution of the nsSNP in the 5
different peptide domains (N-term, e-loops, trans-mem-
brane, i-loops and C-term) was found not to be different
between any of the ligand specific sub-groups of GPCR
proteins, namely peptide receptors, monoamine receptors
and chemokine receptors. We reasoned that the evolu-
tionary constraints on outer- and inner-loops along with
the N-term and C-term regions would be related to the
function of these regions while the constraints on the
trans-membrane regions might be related to their struc-
ture. We, therefore compared the distribution of validated
nsSNP in the 3 major peptide domains (e-loops + N-term
= region 1; trans-membrane = region 2; i-loops + C-term =
region 3). We observed a difference in nsSNP distribution
across the three regions, which approached significance
(Pearson's p-value = 0.06). There was a two-fold decrease
in frequency of occurrence of nsSNP in the TM region of
monoamine receptors as compared to the other sub-
groups of receptors. This indicates that there might per-
haps be a functional selection against variations, acting on
TM domains of monoamine receptors, which is less selec-
tive on the TM domains of peptide receptors, and chem-
okine receptor GPCRs. A recent study reported differences
between the distribution of 'disease causing' and 'non-dis-
ease causing' variations in different sub-groups of GPCR
family members [16]. Our study excluded rare mutations,
which were known to be associated with disease, and
therefore a similar comparison was not possible.
Although HUMAN GPCR-DB database does obtain the
bulk of the information and data from Ensembl and
dbSNP, it is not merely a subset of these major databases.
While Ensembl provides sequence and genetic variation
information, it provides SNP validation information
obtained from public sources, which may include, as
shown in several published studies, up to 50% false posi-
tives. NCBI's dbSNP provides validation-, submitter- and
method-information, yet rates of false positives have
proven to be high. These databases harbor information of
genetic variations for all coding and non-coding regions
of the human genome. The HUMAN GPCR-DB, in addi-
tion to providing this set of information, provides in-
house validation and assay-information for non-validated
nsSNPs. HUMAN GPCR-DB provides natural variation,
mutation, promoter- and peptide-variation information
along with gene structure and peptide 7-TM structure
information and SNP validation information of a focused
group of clinically important genes.
Transcriptional regulatory regions on the 5'-FR of human
genes encode short sequences which serve as targets for
binding of transcription factors (TFs). Eukaryotic TFs tol-
erate considerable sequence variation in their target sites
and recent works in bioinformatics [17-19] have devel-
oped reliable methods to model the DNA binding specif-
icity of individual TFs [20]. Currently the most successful
approach to overcome this information gap is based on
the assumption that gene sequences conserved between
species (here Human and Mouse) would most likely
mediate biological function [21-25]. Our recent study
(our manuscript, 2004) describes a method for the detec-
tion and validation of functionally important SNPs in the
5'-flanking regions of human. The rate of successful detec-
tion of SNPs influencing TFBS using our method is
approximately 70%. This prediction algorithm has been
used to highlight SNPs in 5' flanking regions of the GPCR
in the HUMAN GPCR-DB genes to facilitate selection and
study of functionally important promoter SNPs. The
knowledge of functional promoter SNPs would help us
study disease related GPCR in more details.
The functional domains of human GPCRs have over the
passed decade been dissected by systematically mutating
the peptide sequence [8]. A collection of mutations and
their disease significance and influence on the function of
the protein together with common variations within the
human population would facilitate our understanding of
the variations and disease association. HUMAN GPCR-DB
attempts to merge SNP and mutation information along
with disease information in easily accessible and user-
friendly manner. Although direct links to disease data-
bases would be included in the next release, the existing
information about the source publication can be helpful
in obtaining the relevant details about the mutations.
Current and future updates
Of the 123 nsSNPs without validation information, we
have currently validated 80 SNPs. Future updates would
include information about the remaining nsSNPs, and
any additional which are reported by public databases.
We have also collected 120 published SNPs, which have
as yet not been deposited at public databases, or are in the
process of being deposited. We would have a complete
update of SNP data for every new release of NCBI and
HGVBase SNP tables. New GPCR identification and char-
acterization, or changes in existing GPCR genes or
proteins information would be updated once a year from
Ensembl and SwissProt Databases. PubMed references
would be updated monthly or as often as necessary to
complete the mutation coverage of the 222 GPCR
proteins. Haplotype information and genetic association
studies for available SNPs along with published records
on functional promoter SNPs would be added. A valuable
addition would be to indicate variation frequencies in eth-
nically diverse populations. We are currently adding such
information about the allele frequencies and populations
in the database and would be provided in future updates.BMC Genomics 2004, 5:91 http://www.biomedcentral.com/1471-2164/5/91
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Conclusions
Single-exon GPCRs on average have approximately three
times the number of SNPs as compared to GPCRs with
introns. Among various functional classes of GPCRs,
Monoamine GPRCs have lower number of natural varia-
tions within the trans-membrane domain indicating evo-
lutionary selection against non-synonymous changes
within membrane localizing domain. The HUMAN
GPCR-DB compiles SNPs and mutations in one database.
Using a recently developed method for identification of
functionally important SNPs in the 5'-flanking regions of
human, with approximately 70% success rate, the data-
base highlights such SNPs to facilitate selection and study
of functionally important promoter SNPs.
Methods
The list of Human GPCR genes was compiled by collect-
ing gene names from several different sources and subse-
quently the list was updated by removing duplicates and
entries with incomplete information like peptide frag-
ments, partial sequences and hypothetical proteins. The
Ensembl MART genome server database was queried for
GPCR family members. The Gene Ontology server Amigo
http://www.godatabase.org/cgi-bin/go.cgi was queried
with the search term 'GO:0004930', which describes the
GPCR group of genes. The list of Swiss-Prot and TrEMBL
entries were fetched from GPCRDB [7], ensemble, Inter-
national Union of Pharmacology http://www.iuphar.org.
All the lists were merged and redundancies removed and
Ensembl gene numbers (ENSG) were obtained for all of
the genes from Ensembl genome server. The final list con-
sisted of total of 427 genes with unique ENSG numbers.
Of these 427 genes, 89 genes belonged to the sub-family
of olfactory genes. Also of the 427 genes, 222 had demon-
strable or convincing evidence for GPCR domain structure
and sequence information in Ensembl and SwissProt
databases.
The gene and transcript map information were obtained
from Ensembl databases 'homo_sapien_core_25_34d'
and 'ensemble_mart_25_1', released in September 2004.
The tables for gene mapping, SNP mapping and Human-
Mouse alignment were obtained from ensemble, dbSNP,
HGVBASE and UCSC and installed locally. For the chro-
mosomal and genomic location of SNPs and validation
information, NCBI's dbSNP tables 'snp', 'snpcontigloc',
and 'snpcontiglocusid' and Ensembl's tables 'ContigHit'
and 'locus' were used. Information about the location of
the SNP within protein domains was obtained from
Swissprot using bioperl modules for accessing protein fea-
tures. HGVBase release version 14 was used for obtaining
HGVBASE SNP identities and validation and frequency
information. The flanking sequence information was
obtained from both Ensembl's RefSNP table and by
downloading sequence flat files from dSNP
(ds_flat_chr'1–22. X, Y'.fa);
For mapping Transcription Factor Binding Sites, the TFBS
perl programming system [26] was used. This program
applies position weight matrices (PWM) to DNA
sequences to generate mathematical probability for the
binding of a TF, based on the earlier described thermody-
namics of binding energy [27-29]. Recent reviews and arti-
cles describe methods related to PWM and the
bioinformatics of regulatory site prediction [18,30]. For
determining human-mouse conserved regions, global
best alignments files were downloaded from UCSC. SNPs
in 5' flanking sequences were analyzed according to the
differences in the absolute bind score derived from the
matrices for each TF. A total of 78 factors from vertebrate
class were used, hosted at the TFBS database, JASPAR [31].
MySQL™ version 4.0 with ActiveState™ Komodo version
2.3 as perl programming IDE and bioperl modules ver-
sion 1.2 were used for database development. The web
server technology used was Apache™ 2.0 with PHP 4.0, as
supplied by NuSphere™ version 3.0. Non-synonymous
SNPs were identified from all the SNPs, after the construc-
tion of the GPCR SNP database based on data acquired
directly from dbSNP and HGVBASE. Validation of SNPs
was carried out by DynaMetrix Inc., UK, using the DASH
platform [32]. The allele frequency validation was per-
formed on DNA samples from 16 anonymous individuals
of Nordic descent, with the Institutional Review Board
Approval KI 02-544.
Abbreviations
7TM: 7 transmembrane; GPCR:G-protein Coupled Recep-
tors; SNP: single Nucleotide Polymorphism; nsSNP : non-
synonymous SNPs; cSNP : coding SNP; rSNP : regulatory
SNPs; N-term : N terminus; C-term : C terminus; e-loop :
external loops; i-loop : internal loops.
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